Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ACR | P10323 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502531 | 0.83 | MEN1 (0.40) | KCNQ2MAPTALDH1A1KDM4EGAA | |
| SCHEMBL6505072 | 0.80 | ROCK2 (0.40) | MAPTALDH1A1GAA | |
| SCHEMBL6503082 | 0.80 | ROCK2 (0.42) | MAPTALOX15 | |
| SCHEMBL6493590 | 0.79 | LMNA (0.42) | MAPTALDH1A1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL6494612 | 0.79 | LMNA (0.41) | MAPTALDH1A1KDM4EGAA | |
| SCHEMBL6496201 | 0.76 | POLB (0.54) | MAPTALDH1A1GAA | |
| SCHEMBL6504814 | 0.72 | ACLY (0.38) | MAPTALDH1A1ALOX15GAA | |
| SCHEMBL7073827 | 0.72 | MAPT (0.41) | BRD4MAPTALDH1A1KDM4E | |
| SCHEMBL6501121 | 0.72 | LTB4R (0.37) | MAPTALDH1A1ALOX15 | |
| SCHEMBL6494231 | 0.72 | ALOX15 (0.36) | MAPTALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | claimed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | claimed |
| EP-1294686-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1294686-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | ALOX15, ALOX5, ALOX12 | TLR8 4245/4885TLR7 4488/4885KCNQ2 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.